查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1317914

人类乳突病毒疫苗市场：依适应症、类型、通路分类 - 全球预测 2023-2030

Human Papillomavirus Vaccine Market by Disease Indication, Type, Distribution Channel - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

全球人类乳突病毒疫苗市场预计将以 7.01%的年复合成长率大幅成长，到 2023 年达到 43.0509 亿美元，预计到 2030 年将达到惊人的 692948 万美元。

FPNV定位矩阵

FPNV定位矩阵对于评估全球人类乳突病毒疫苗市场至关重要。透过检查业务策略和产品满意度的关键指标，我们对供应商进行全面评估，使您能够根据您的特定需求做出明智的资讯。这种进阶分析将供应商分为四个像限，并取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市占率分析

市场占有率分析可以深入了解供应商在特定市场领域的当前地位。比较供应商对总收入、基本客群和其他关键指标的贡献，可以帮助公司更好地了解他们在争夺市场份额时的表现以及面临的情况。该分析还揭示了特定行业的竞争程度、累积和合併的优势以及研究基准年的合併特征。

本报告提供了以下几点见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开发：提供有关利润丰厚的新兴市场的详细资讯，并分析其在成熟市场的渗透率。

3. 市场多元化：提供有关新产品发布、未开发领域、最新发展和投资的详细资讯。

4.市场趋势：全面了解COVID-19、俄罗斯-乌克兰衝突和高通膨的累积影响。

5.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、法规状况、专利状况、製造能力等进行综合评估。

6. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告回答了以下问题：

1. 人类乳突病毒疫苗的全球市场规模和预测是多少？

2.在预测期内，COVID-19对全球人类乳突病毒疫苗市场的阻碍因素与影响为何？

3.在预测期内，全球人类乳突病毒疫苗市场需要投资哪些产品/细分市场/应用/领域？

4.全球人类乳突病毒疫苗市场的竞争策略是什么？

5.全球人类乳突病毒疫苗市场的技术趋势和法律规范是什么？

6.全球人类乳突病毒疫苗市场主要厂商的市占率是多少？

7. 哪些型态和策略措施被认为适合进入人类乳突病毒疫苗全球市场？

目录

第1章前言

第2章调查方法

第3章执行摘要

第4章市场概况

第5章市场洞察

  • 市场动态
    • 促进因素
      • 人类乳突病毒疫苗在癌症治疗的相关用途
      • 广受讚誉为突破性的医药创新
      • 政府资助癌症研究和开发
    • 抑制因素
      • 基础设施供应不足
    • 机会
      • 全球卫生界对 HPV 引入的支持日益增长
      • HPV 疫苗製造流程的进步
    • 任务
      • 缺乏社区参与来提高对 HPV 诊断和治疗的认识
  • 市场趋势
  • COVID-19 的累积影响
  • 俄罗斯-乌克兰衝突的累积影响
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范
  • 客户客製化
    • 临床试验和趋势
    • 价格分析和趋势

第6章人类乳突病毒疫苗市场：依疾病适应症

  • 肛门癌
  • 子宫颈癌
  • 尖圭湿疣
  • 口咽癌
  • 阴茎癌
  • 阴道癌
  • 外阴癌

第7章人类乳突病毒疫苗市场：依类型

  • 二价
  • 四价和九价

第8章人类乳突病毒疫苗市场：依通路划分

  • 政府机关
  • 医生
  • 公私联盟
  • 批发商

第9章美洲人类乳突病毒疫苗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太人类乳突病毒疫苗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第11章欧洲、中东和非洲人乳头瘤病毒疫苗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第12章竞争形势

  • FPNV定位矩阵
  • 市占率分析：主要企业
  • 竞争情境分析：主要企业

第13章上市公司名单

第14章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-436B79517C78

The Global Human Papillomavirus Vaccine Market is forecasted to grow significantly, with a projected USD 4,305.09 million in 2023 at a CAGR of 7.01% and expected to reach a staggering USD 6,929.48 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Human Papillomavirus Vaccine Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Human Papillomavirus Vaccine Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Disease Indication, market is studied across Anal Cancer, Cervical Cancer, Genital Warts, Oropharyngeal Cancer, Penile Cancer, Vaginal Cancer, and Vulvar Cancer. The Oropharyngeal Cancer is projected to witness significant market share during forecast period.

Based on Type, market is studied across Bivalent and Tetravalent & Nonavalent. The Bivalent is projected to witness significant market share during forecast period.

Based on Distribution Channel, market is studied across Government Entities, Physicians, Public & Private Alliances, and Wholesalers. The Government Entities is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Human Papillomavirus Vaccine Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Human Papillomavirus Vaccine Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Human Papillomavirus Vaccine Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Human Papillomavirus Vaccine Market?

4. What is the competitive strategic window for opportunities in the Global Human Papillomavirus Vaccine Market?

5. What are the technology trends and regulatory frameworks in the Global Human Papillomavirus Vaccine Market?

6. What is the market share of the leading vendors in the Global Human Papillomavirus Vaccine Market?

7. What modes and strategic moves are considered suitable for entering the Global Human Papillomavirus Vaccine Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Human Papillomavirus Vaccine Market, by Disease Indication, 2022 vs 2030
  • 4.3. Human Papillomavirus Vaccine Market, by Type, 2022 vs 2030
  • 4.4. Human Papillomavirus Vaccine Market, by Distribution Channel, 2022 vs 2030
  • 4.5. Human Papillomavirus Vaccine Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Human papillomavirus vaccines associated uses for treatment of cancer
      • 5.1.1.2. Widely commended as a sweeping pharmaceutical innovation
      • 5.1.1.3. Funding by the government for R&D of cancer
    • 5.1.2. Restraints
      • 5.1.2.1. Inadequate delivery of infrastructure
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing support for HPV introduction among the global health community
      • 5.1.3.2. Advancements in manufacturing process of HPV vaccines
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of community engagement to generate awareness regarding diagnosis and treatment of HPV
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization
    • 5.9.1. Clinical Trials & Trends
    • 5.9.2. Pricing Analysis & Trend

6. Human Papillomavirus Vaccine Market, by Disease Indication

  • 6.1. Introduction
  • 6.2. Anal Cancer
  • 6.3. Cervical Cancer
  • 6.4. Genital Warts
  • 6.5. Oropharyngeal Cancer
  • 6.6. Penile Cancer
  • 6.7. Vaginal Cancer
  • 6.8. Vulvar Cancer

7. Human Papillomavirus Vaccine Market, by Type

  • 7.1. Introduction
  • 7.2. Bivalent
  • 7.3. Tetravalent & Nonavalent

8. Human Papillomavirus Vaccine Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Government Entities
  • 8.3. Physicians
  • 8.4. Public & Private Alliances
  • 8.5. Wholesalers

9. Americas Human Papillomavirus Vaccine Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Human Papillomavirus Vaccine Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Human Papillomavirus Vaccine Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. HUMAN PAPILLOMAVIRUS VACCINE MARKET RESEARCH PROCESS
  • FIGURE 2. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2022 VS 2030
  • FIGURE 3. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2022 VS 2030 (%)
  • FIGURE 5. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
  • FIGURE 6. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
  • FIGURE 7. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 8. HUMAN PAPILLOMAVIRUS VACCINE MARKET DYNAMICS
  • FIGURE 9. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. HUMAN PAPILLOMAVIRUS VACCINE MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 17. HUMAN PAPILLOMAVIRUS VACCINE MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. HUMAN PAPILLOMAVIRUS VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 5. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY ANAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENITAL WARTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY OROPHARYNGEAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PENILE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VAGINAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VULVAR CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY BIVALENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TETRAVALENT & NONAVALENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 16. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GOVERNMENT ENTITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PHYSICIANS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PUBLIC & PRIVATE ALLIANCES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY WHOLESALERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. HUMAN PAPILLOMAVIRUS VACCINE MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 148. HUMAN PAPILLOMAVIRUS VACCINE MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 149. HUMAN PAPILLOMAVIRUS VACCINE MARKET LICENSE & PRICING